Silence Therapeutics Ratios (2018-2026) | SLN

Ratios Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
Gross Margin (Quarter) 82.16%-322.13%-142.92%91.95%61.97%62.05%59.75%64.71%97.39%
EBT Margin (Quarter) -13.17%-2,440.88%-2,369.49%49.90%-20,091.55%-12,207.14%-13,180.50%-34,617.65%-3,544.31%
EBIT Margin (Quarter) -35.55%-2,923.50%-2,002.47%-17.20%-20,006.34%-10,697.77%-16,505.66%-36,650.00%-3,729.15%
EBITDA Margin (Quarter) -35.55%-2,923.50%-2,002.47%-17.20%-20,006.34%-10,697.77%-16,505.66%-36,650.00%-3,729.15%
Operating Margin (Quarter) -35.55%-2,923.50%-2,002.47%-17.20%-20,006.34%-10,697.77%-16,505.66%-36,650.00%-3,729.15%
Net Margin (Quarter) -14.73%-2,469.38%-2,372.76%95.88%-20,091.55%-12,211.61%-13,181.13%-34,617.65%-3,544.31%
FCF Margin (Quarter) -58.24%-686.75%-1,666.49%-111.64%-8,671.13%-9,720.09%-6,888.68%-50,929.41%-3,697.39%
Efficiency
Assets Average (Quarter) 193.97M175.27M156.01M139.12M123.28M
Asset Utilization Ratio (Quarter) 0.140.160.170.000.01
Leverage & Solvency
Interest Coverage Ratio (Quarter) -0.07-77.88
Times Interest Earned (Quarter) -0.07-77.88
Valuation
Enterprise Value (Quarter) -27.66M-17.38M-38.22M-99.13M-64.30M-67.06M-186.07M-208.15M-114.16M-122.36M-85.11M-134.52M
Return Ratios
Return on Sales (Quarter) 0.00%-0.25%-0.24%0.01%-2.01%-1.22%-1.32%-3.46%-0.35%
Return on Capital Employed (Quarter) -49.31%-54.03%-59.85%-72.57%-69.49%
Return on Assets (Quarter) 0.00%0.00%0.00%-0.01%-0.01%